<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01565148</url>
  </required_header>
  <id_info>
    <org_study_id>2010-007-03-DME</org_study_id>
    <nct_id>NCT01565148</nct_id>
  </id_info>
  <brief_title>A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)</brief_title>
  <acronym>iDEAL</acronym>
  <official_title>A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema With Involvement of the FoveAL Center (the iDEAL Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>iCo Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To assess the safety of repeated iCo-007 intravitreal injections in treatment of
           subjects with diabetic macular edema as monotherapy and in combination with ranibizumab
           or laser photocoagulation

        -  To assess the change in visual acuity and retinal thickness on optical coherence
           tomography (OCT) from baseline to month 8 and month 12
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Patient's disease progressed and Vision Dropped which led to exit from the study
  </why_stopped>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VA From Baseline to Month 8</measure>
    <time_frame>Baseline to month 8</time_frame>
    <description>The primary efficacy variable is the change in visual acuity (mean change in number of letters) from baseline to month 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in a Given Study Arm Experiencing the Same Drug-related Serious Adverse Event as a Measure of Safety and Tolerability</measure>
    <time_frame>Baseline to month 8</time_frame>
    <description>Safety of repeated iCo-007 intravitreal injections in treatment of subjects with Diabetic Macular Edema (DME) as monotherapy and in combination with ranibizumab or laser photocoagulation. Serious consideration will be given if 2 or more patients in a particular treatment arm experience the same drug-related serious adverse event;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VA From Baseline to Month 12</measure>
    <time_frame>Baseline to month 12</time_frame>
    <description>The primary efficacy variable is the change in visual acuity (mean change in number of letters) from baseline to month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Retinal Thickness Measured by OCT From Baseline to Month 8</measure>
    <time_frame>Baseline to month 8</time_frame>
    <description>Group 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Retinal Thickness Measured</measure>
    <time_frame>Baseline to month 12</time_frame>
    <description>measured by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of iCo-007 Treatment Effect</measure>
    <time_frame>Baseline to month 12</time_frame>
    <description>treatment effect as measured by VA and OCY thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)of iCo-007 After Multiple Injections</measure>
    <time_frame>Baseline to month 12</time_frame>
    <description>cmax</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: iCo-007 350 mcg
iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: iCo-007 700 mcg
iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: iCo-007 350 mcg and Laser
iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Ranibizumab and iCo-007 350 mcg
Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iCo-007 350 mcg</intervention_name>
    <description>iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iCo-007 700 mcg</intervention_name>
    <description>iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Group 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iCo-007 350 mcg and Laser</intervention_name>
    <description>iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Group 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab and iCo-007 350 mcg</intervention_name>
    <description>Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later</description>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Group 4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Have diabetes mellitus type I or II (insulin or non-insulin dependent) with HbA1c
             ≥5.5% and HbA1c ≤13%; have non-proliferative diabetic retinopathy, or inactive
             proliferative diabetic retinopathy, or proliferative diabetic retinopathy with a
             reasonable expectation that panretinal photocoagulation will not be required during
             the study follow-up period

          -  Have diabetic macular edema with central subfield thickness of ≥250 microns (confirmed
             by Stratus Time-Domain(TD) OCT

          -  Have best corrected visual acuity (ETDRS) that is Snellen equivalent of

               -  20/32 and ≥20/320, inclusive

          -  Be willing and able to sign an approved written informed consent. If a patient has a
             central nervous system disorder (i.e. dementia) that will not allow him/her to
             understand the consent independently, the patient will not be allowed to join the
             study

          -  Be able to attend all scheduled study visits

          -  Women who are not lactating or pregnant and are willing to use adequate contraception
             during the study period, if appropriate

        Exclusion Criteria:

          -  Have macular or perimacular edema secondary to an etiology other than diabetes

          -  Have concurrent retinal diseases other than diabetic retinopathy

          -  Have additional ocular diseases compromising visual acuity and/or interfering with
             study assessments; patients who have glaucoma but deemed stable (intraocular pressure
             ≤ 25 mmHg at screening) on medications or status post surgery, may participate in the
             study

          -  Participant has a history of prior pars plana vitrectomy

          -  Subjects with significant cataract or or posterior capsular opacification that may
             need intervention within one year or vitreous opacity that hinder study assessment
             (i.e.fundus examination) which requires intervention within a year

          -  Subjects who have DME with severe capillary non-perfusion (avascular zone diameter
             &gt;1,000 microns)

          -  Have an allergy to fluorescein dye

          -  Have terminal renal disease (on active kidney dialysis), cerebral vascular
             accident(including TIA), myocardial infarction or congestive heart disease within 6
             months of study enrollment, liver damage (2x upper limit of normal range for aspartate
             aminotransferase (AST), Alanine aminotransferase (ALT) or total bilirubin). Patients
             who may have received renal transplant in the past and now have stable renal function,
             may participate in the study

          -  Subjects with systolic blood pressure higher than 180 mm Hg or diastolic above 100 mm
             Hg, with or without anti-hypertensive treatment

          -  Have a history of panretinal photocoagulation (PRP) in the study eye within 3 months
             of study entry or are likely to have PRP in the study eye during study participation

          -  Had macular photocoagulation or ocular surgery within 3 months of study entry in the
             study eye

          -  Received intraocular or periocular injection of steroids in the study eye (e.g.,
             triamcinolone) within 3 months of study entry or anti-angiogenic drugs (pegaptanib
             sodium, ranibizumab, bevacizumab, VEGF-TRAP, protein kinase C inhibitor, etc.) within
             2 months of study entry; history of usage of topical or systemic steroids within 3
             months of study entry is not an exclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana V. Do, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanley M Truhlsen Eye Institute, University of Nebraska Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austin Retina Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael J. Tolentino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Retina Macula Disease</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prema Abraham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Black Hills Regional Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugene Lit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Bay Retina Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael J. Elman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elman Retina Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas A. Barnard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Retina Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas A. Ciulla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midwest Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard B. Rosen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Eye and Ear Infirmary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henry L. Hudson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Centers, P.C.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pravin Dugel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Consultants of Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregg T. Kokame, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Consultants of Hawaii, Pali Momi Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David M. Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Consultants Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larry S. Halperin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Group of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Goergios Papastergio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Institute of Hawaii</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ron P. Gallemore, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Macula Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian B. Berger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Homayoun Tabandeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Vitreous Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis M. Marcus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southeast Retina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert S. Wirthlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spokane Eye Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Callanan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Retina Associates in Arlington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl G. Csaky, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Retina Associates in Dallas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Surendar Purohit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TLC Eye Care &amp; Laser Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor H. Gonzalez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Valley Retina Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louis Glazer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vitreo-Retinal Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dean Eliott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear Infirmary, Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanley M Truhlsen Eye Institute</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2012</study_first_submitted>
  <study_first_submitted_qc>March 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2012</study_first_posted>
  <results_first_submitted>October 11, 2016</results_first_submitted>
  <results_first_submitted_qc>July 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 30, 2017</results_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema (DME)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>iCo-007 350 mcg</title>
          <description>iCo-007 350 mcg: iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4</description>
        </group>
        <group group_id="P2">
          <title>iCo-007 700 mcg</title>
          <description>iCo-007 700 mcg: iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4</description>
        </group>
        <group group_id="P3">
          <title>iCo-007 350 mcg and Laser</title>
          <description>iCo-007 350 mcg and Laser: iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation</description>
        </group>
        <group group_id="P4">
          <title>Ranibizumab and iCo-007 350 mcg</title>
          <description>Ranibizumab Plus iCo-007 350 mcg: Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Rescue Therapy</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>iCo-007 350 mcg: iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>iCo-007 700 mcg: iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>iCo-007 350 mcg Plus Laser: iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation</description>
        </group>
        <group group_id="B4">
          <title>Group 4</title>
          <description>Ranibizumab Plus iCo-007 350 mcg: Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="47"/>
            <count group_id="B4" value="45"/>
            <count group_id="B5" value="185"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" spread="8.91"/>
                    <measurement group_id="B2" value="62.8" spread="9.7"/>
                    <measurement group_id="B3" value="61.4" spread="9.72"/>
                    <measurement group_id="B4" value="61.2" spread="7.29"/>
                    <measurement group_id="B5" value="62.2" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Best Corrected Visual Acuity (BCVA)</title>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="12.3"/>
                    <measurement group_id="B2" value="58.7" spread="12.49"/>
                    <measurement group_id="B3" value="59.8" spread="13.78"/>
                    <measurement group_id="B4" value="61.5" spread="14.03"/>
                    <measurement group_id="B5" value="59.3" spread="13.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in VA From Baseline to Month 8</title>
        <description>The primary efficacy variable is the change in visual acuity (mean change in number of letters) from baseline to month 8</description>
        <time_frame>Baseline to month 8</time_frame>
        <population>The results are from the participants which completed the primary end point and for which the data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>iCo-007 350 mcg: iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>iCo-007 700 mcg: iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>iCo-007 350 mcg Plus Laser: iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Ranibizumab Plus iCo-007 350 mcg: Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VA From Baseline to Month 8</title>
          <description>The primary efficacy variable is the change in visual acuity (mean change in number of letters) from baseline to month 8</description>
          <population>The results are from the participants which completed the primary end point and for which the data is available.</population>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.07" spread="18.20"/>
                    <measurement group_id="O2" value="-24.46" spread="24.02"/>
                    <measurement group_id="O3" value="-15.22" spread="24.62"/>
                    <measurement group_id="O4" value="-18.28" spread="30.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in a Given Study Arm Experiencing the Same Drug-related Serious Adverse Event as a Measure of Safety and Tolerability</title>
        <description>Safety of repeated iCo-007 intravitreal injections in treatment of subjects with Diabetic Macular Edema (DME) as monotherapy and in combination with ranibizumab or laser photocoagulation. Serious consideration will be given if 2 or more patients in a particular treatment arm experience the same drug-related serious adverse event;</description>
        <time_frame>Baseline to month 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>iCo-007 350 mcg: iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>iCo-007 700 mcg: iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>iCo-007 350 mcg Plus Laser: iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Ranibizumab Plus iCo-007 350 mcg: Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in a Given Study Arm Experiencing the Same Drug-related Serious Adverse Event as a Measure of Safety and Tolerability</title>
          <description>Safety of repeated iCo-007 intravitreal injections in treatment of subjects with Diabetic Macular Edema (DME) as monotherapy and in combination with ranibizumab or laser photocoagulation. Serious consideration will be given if 2 or more patients in a particular treatment arm experience the same drug-related serious adverse event;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in VA From Baseline to Month 12</title>
        <description>The primary efficacy variable is the change in visual acuity (mean change in number of letters) from baseline to month 12</description>
        <time_frame>Baseline to month 12</time_frame>
        <population>The study was terminated prior to month 12. No data was collected and 0 participants were analyzed at month 12</population>
        <group_list>
          <group group_id="O1">
            <title>iCo-007 350 mcg</title>
            <description>iCo-007 350 mcg: iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4</description>
          </group>
          <group group_id="O2">
            <title>iCo-007 700 mcg</title>
            <description>iCo-007 700 mcg: iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4</description>
          </group>
          <group group_id="O3">
            <title>iCo-007 350 mcg and Laser</title>
            <description>iCo-007 350 mcg and Laser: iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab and iCo-007 350 mcg</title>
            <description>Ranibizumab Plus iCo-007 350 mcg: Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VA From Baseline to Month 12</title>
          <description>The primary efficacy variable is the change in visual acuity (mean change in number of letters) from baseline to month 12</description>
          <population>The study was terminated prior to month 12. No data was collected and 0 participants were analyzed at month 12</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Retinal Thickness Measured by OCT From Baseline to Month 8</title>
        <description>Group 1</description>
        <time_frame>Baseline to month 8</time_frame>
        <population>Some participants opted out of the month 8 OCT.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>iCo-007 350 mcg: iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>iCo-007 700 mcg: iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>iCo-007 350 mcg Plus Laser: iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Ranibizumab Plus iCo-007 350 mcg: Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Retinal Thickness Measured by OCT From Baseline to Month 8</title>
          <description>Group 1</description>
          <population>Some participants opted out of the month 8 OCT.</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.68" spread="176.31"/>
                    <measurement group_id="O2" value="-160.22" spread="177.36"/>
                    <measurement group_id="O3" value="-54.17" spread="125.35"/>
                    <measurement group_id="O4" value="-92.10" spread="185.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Retinal Thickness Measured</title>
        <description>measured by OCT</description>
        <time_frame>Baseline to month 12</time_frame>
        <population>The study was terminated prior to month 12. No data was collected and 0 participants were analyzed at month 12</population>
        <group_list>
          <group group_id="O1">
            <title>iCo-007 350 mcg</title>
            <description>iCo-007 350 mcg: iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4</description>
          </group>
          <group group_id="O2">
            <title>iCo-007 700 mcg</title>
            <description>iCo-007 700 mcg: iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4</description>
          </group>
          <group group_id="O3">
            <title>iCo-007 350 mcg and Laser</title>
            <description>iCo-007 350 mcg and Laser: iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab and iCo-007 350 mcg</title>
            <description>Ranibizumab Plus iCo-007 350 mcg: Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Retinal Thickness Measured</title>
          <description>measured by OCT</description>
          <population>The study was terminated prior to month 12. No data was collected and 0 participants were analyzed at month 12</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of iCo-007 Treatment Effect</title>
        <description>treatment effect as measured by VA and OCY thickness</description>
        <time_frame>Baseline to month 12</time_frame>
        <population>The study was terminated prior to month 12. No data was collected and 0 participants were analyzed at month 12</population>
        <group_list>
          <group group_id="O1">
            <title>iCo-007 350 mcg</title>
            <description>iCo-007 350 mcg: iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4</description>
          </group>
          <group group_id="O2">
            <title>iCo-007 700 mcg</title>
            <description>iCo-007 700 mcg: iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4</description>
          </group>
          <group group_id="O3">
            <title>iCo-007 350 mcg and Laser</title>
            <description>iCo-007 350 mcg and Laser: iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab and iCo-007 350 mcg</title>
            <description>Ranibizumab Plus iCo-007 350 mcg: Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of iCo-007 Treatment Effect</title>
          <description>treatment effect as measured by VA and OCY thickness</description>
          <population>The study was terminated prior to month 12. No data was collected and 0 participants were analyzed at month 12</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Plasma Concentration (Cmax)of iCo-007 After Multiple Injections</title>
        <description>cmax</description>
        <time_frame>Baseline to month 12</time_frame>
        <population>The study was terminated prior to month 12. No data was collected and 0 participants were analyzed at month 12</population>
        <group_list>
          <group group_id="O1">
            <title>iCo-007 350 mcg</title>
            <description>iCo-007 350 mcg: iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4</description>
          </group>
          <group group_id="O2">
            <title>iCo-007 700 mcg</title>
            <description>iCo-007 700 mcg: iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4</description>
          </group>
          <group group_id="O3">
            <title>iCo-007 350 mcg and Laser</title>
            <description>iCo-007 350 mcg and Laser: iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab and iCo-007 350 mcg</title>
            <description>Ranibizumab Plus iCo-007 350 mcg: Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax)of iCo-007 After Multiple Injections</title>
          <description>cmax</description>
          <population>The study was terminated prior to month 12. No data was collected and 0 participants were analyzed at month 12</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>iCo-007 350 mcg: iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>iCo-007 700 mcg: iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>iCo-007 350 mcg Plus Laser: iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation</description>
        </group>
        <group group_id="E4">
          <title>Group 4</title>
          <description>Ranibizumab Plus iCo-007 350 mcg: Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular Adverse Events</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Ocular Adverse Events</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Other Adverse Events - Ocular</sub_title>
                <counts group_id="E1" events="107" subjects_affected="28" subjects_at_risk="47"/>
                <counts group_id="E2" events="119" subjects_affected="32" subjects_at_risk="46"/>
                <counts group_id="E3" events="88" subjects_affected="29" subjects_at_risk="47"/>
                <counts group_id="E4" events="99" subjects_affected="34" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other Adverse Events - Systemic</sub_title>
                <counts group_id="E1" events="58" subjects_affected="20" subjects_at_risk="47"/>
                <counts group_id="E2" events="63" subjects_affected="23" subjects_at_risk="46"/>
                <counts group_id="E3" events="45" subjects_affected="23" subjects_at_risk="47"/>
                <counts group_id="E4" events="69" subjects_affected="22" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Quan Dong Nguyen</name_or_title>
      <organization>University of Nebraska</organization>
      <phone>4025592020</phone>
      <email>quan.nguyen@unmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

